Skip to main content
Watch Insiders
MDGLHealthcare

Madrigal Pharmaceuticals Inc (MDGL) Insider Trading

In the last 90 days, 2 Madrigal Pharmaceuticals Inc (MDGL) insiders reported no open-market purchases and 2 sales totaling $6,581,138. Source: SEC Form 4 filings.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
0
90-day purchase value
$0.00
Corporate buyers
0
Latest transaction
Sep 11, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Sep 11, 2026William John SiboldPresident and CEOSale11,583$538.65$6,239,198
Aug 17, 2026Shannon T KelleyGeneral CounselSale664$514.97$341,940
Jul 20, 2026William John SiboldPresident and CEOSale2,500$547.30$1,368,254
Jun 1, 2026David SoergelChief Medical OfficerSale1,042$495.74$516,561
May 22, 2026Richard S LevyCorporate insiderSale5,682$515.44$2,928,716
May 18, 2026David SoergelChief Medical OfficerSale844$515.90$435,420

Common questions

MDGL insider trading FAQ

Are MDGL insiders buying or selling?
Over the last 90 days, MDGL insiders were net sellers, reporting $0.00 of open-market purchases and $6,581,138 of sales.
When was the last MDGL insider purchase?
No open-market insider purchase of Madrigal Pharmaceuticals Inc stock was reported in the last 90 days.
Where does MDGL insider trading data come from?
Watch Insiders reads the SEC Form 4 filings that Madrigal Pharmaceuticals Inc officers, directors, and 10% owners submit to EDGAR, and refreshes this page daily.